research
∙
04/17/2023
Visualizing hypothesis tests in survival analysis under anticipated delayed effects
What can be considered an appropriate statistical method for the primary...
share
research
∙
10/17/2022
A Bayesian design for dual-agent dose optimization with targeted therapies
In this article, we propose a phase I-II design in two stages for the co...
research
∙
08/11/2022
Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
In parametric Bayesian designs of early phase cancer clinical trials wit...
research
∙
01/25/2022
Stratified modestly-weighted log-rank tests in settings with an anticipated delayed separation of survival curves
Delayed separation of survival curves is a common occurrence in confirma...
research
∙
09/29/2021
Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials
Phase I-II cancer clinical trial designs are intended to accelerate drug...
research
∙
06/15/2021
A Bayesian adaptive design for dual-agent phase I-II cancer clinical trials combining efficacy data across stages
Integrated phase I-II clinical trial designs are efficient approaches to...
research
∙
02/10/2021
Designing group sequential clinical trials when a delayed effect is anticipated: A practical guidance
A common feature of many recent trials evaluating the effects of immunot...
research
∙
05/19/2020
A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching
In confirmatory cancer clinical trials, overall survival (OS) is normall...
research
∙
08/28/2019
Quantifying treatment differences in confirmatory trials with delayed effects
Dealing with non-proportional hazards is increasingly common nowadays wh...
research
∙
09/12/2018
A Bayesian adaptive design in cancer phase I/II trials with drug combinations using escalation with overdose control (EWOC) and adaptive randomization
The use of drug combinations in clinical trials is increasingly common d...
research
∙
06/29/2018
